BioSpace News Archive

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved TREMFYA®

Horizon Pharma plc announced its fourth-quarter and full-year 2018 financial results and provided its full-year 2019 net sales and adjusted EBITDA guidance.

Healthcare across the globe is in a phase of digital transformation, striving firmly to improve aspects of cost, quality, and outcomes, and leveraging information technology and digital components as part of evolutionary change.

Lifestyle Delivery Systems Inc. (CSE: LDS), (OTCQX: LDSYF), (Frankfurt: LD6, WKN: A14XHT) (“LDS” or the “Company”) is proud to announce that as of Tuesday, February 27, 2019, Lifestyle Delivery Systems Inc. has signed a Memorandum of Understanding to enter into a Joint Venture (the “JV”) with National Green Biomed Ltd (“NGB”).

Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced the appointment of Dr. Stephana Patton as the Company’s General Counsel, Corporate Secretary, and Chief Compliance Officer.

Houston Methodist Hospital, a leading academic medical center in Texas that fosters innovation for potential clinical application, is joining the TriNetX global health research network to enhance its ability to provide real-world data for study feasibility, facilitate academic collaboration, and increase participation in industry-sponsored clinical trials.

Acurx Pharmaceuticals, LLC (“Acurx” or the “Company”), a privately-held, clinical stage, biopharmaceutical company developing new antibiotics for difficult-to-treat bacterial infections, announced today that its lead product candidate, ACX-362E, has successfully completed the 32-subject, double-blinded, placebo-controlled, single-ascending dose portion of this first-in-man Phase 1 clinical trial.

CareFirst BlueCross BlueShield (CareFirst), the mid-Atlantic region’s largest health insurer, has been named by the Ethisphere Institute as one of the “World’s Most Ethical Companies” in 2019.

IBSA Pharma Inc. announced that its Tirosint-SOL (levothyroxine sodium) oral solution is now available in the US market for the treatment of hypothyroidism and pituitary thyrotropin suppression.

Semler Scientific, Inc. (OTCQB: SMLR), an emerging growth company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers, today reported financial results for the three months and year ended December 31, 2018.